Policy and Regulation · 1 October 2026 to 1 October 2026 · 1 headlines · STAT
STAT Plus: Invivyd’s pursuit of a Covid vaccine alternative gets a lift, but an FDA hurdle may await
Invivyd's efforts to develop an alternative to Covid vaccines received a boost, though the company may still face a regulatory obstacle at the FDA.
As it ran
1 October 2026
- STAT Plus: Invivyd’s pursuit of a Covid vaccine alternative gets a lift, but an FDA hurdle may await STAT
More from US healthcare
- STAT Plus: Sanofi, Regeneron expand partnership after Dupixent success 1 October 2026
- STAT Plus: In Shanghai’s ‘Science City,’ China’s ascendant biotechs make their pitch to the world 1 October 2026
- CMS drug pricing model expansion 1 October 2026
- CMS sets GLOBE ‘most favored nation’ Medicare drug price model 1 October 2026
- GOP States Challenge Democratic-Led States' Abortion 'Shield' Laws at Supreme Court 1 October 2026
- How the 340B fight is squeezing rural hospitals and clinics 1 October 2026
- STAT Plus: A major insurer on how it may replicate Medicare’s chronic-care experiment 1 October 2026
- STAT Plus: Trump’s watered-down Medicare drug pricing rule saves 96% less than initial proposal 1 October 2026